SynthesisFrontiers in oncology2025
Prognostic value of the systemic immune-inflammation index in bladder cancer: an update evidence-based analysis.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bladder cancer (BC) prognosis remains challenging to predict accurately with conventional tools. Systemic immune-inflammation index (SII) has emerged as a promising biomarker reflecting the tumor microenvironment. However, existing studies are limited by small sample sizes, heterogeneous designs, and inconsistent endpoints. This updated meta-analysis aims to comprehensively evaluate the association between high SII and key survival outcomes in BC patients. Methods: We systematically searched PubMed, Embase, Web of Science, and Cochrane up to August 2025. Cohort studies reporting hazard ratios (HRs) for overall survival (OS), recurrence-free survival (RFS), progression-free survival (PFS), or cancer-specific survival (CSS) comparing high vs. low SII groups in histologically confirmed BC were included. Study quality was assessed using the Newcastle-Ottawa Scale. Pooled HRs with 95% confidence intervals (CIs) were calculated using a random-effects model. Subgroup analyses by pathological type (NMIBC vs. MIBC) and sensitivity analyses were performed. Publication bias was evaluated via funnel plots and Egger's test. Results: Sixteen cohort studies involving 2,352 patients were analyzed. Meta-analysis revealed that elevated SII was significantly associated with worse OS (HR=1.66, 95% CI: 1.30-2.12, P < 0.0001) and RFS (HR=1.50, 95% CI: 1.28-1.76, P < 0.00001), with substantial heterogeneity (OS: I² = 81%; RFS: I² = 59%). Subgroup analysis showed significant predictive value of SII for RFS in both NMIBC (HR=1.55, 95% CI: 1.27-1.89, P < 0.0001; heterogeneity reduced to I² = 37%) and MIBC (HR=1.13, 95% CI: 1.01-1.26, P=0.03). However, OS subgroup associations for NMIBC (HR=1.15, P=0.50) and MIBC (HR=1.92, P=0.07) were non-significant. No significant associations were found for PFS (HR=1.55, 95% CI: 0.92-2.60, P=0.10, I² = 68%) or CSS (HR=1.50, 95% CI: 0.95-2.37, P=0.08, I² = 69%), likely due to limited study numbers (4 and 3, respectively). Significant publication bias was detected for OS and RFS. Conclusion: Elevated SII is significantly associated with poorer overall and recurrence-free survival in bladder cancer patients, particularly highlighting its potential predictive value for recurrence risk in NMIBC. However, significant heterogeneity, publication bias, and retrospective design limitations necessitate caution in interpretation. Future large-scale, prospective studies with standardized SII measurement and dynamic monitoring are crucial to validate its clinical utility and define optimal cut-offs for integration into risk-stratified management strategies. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251145769, Prospero identifier, CRD420251145769.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.